Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions

Isela Velazquez, Blanche P. Alter
American journal of hematology · 2004 · vol. 77(3) , pp. 257–267 · doi:10.1002/ajh.20183 · PMID:15495253 · W2105862823
Review OA: closed CC0 ⤵ 6 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This review of 133 cases found that androgen use, both oral and parenteral, is associated with liver tumors in Fanconi anemia and non-Fanconi anemia patients, with specific androgens correlating to tumor type.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The association between anabolic androgenic steroids and liver tumors was first noted in patients with Fanconi's anemia (FA). The hypotheses which led to this review were as follows: (1) androgen-treated individuals who do not have FA are also at risk of liver tumors; (2) parenteral as well as oral androgens may be responsible for liver tumors; (3) FA patients develop liver tumors after smaller and briefer androgen exposure than non-FA individuals; (4) the risk of hepatic neoplasms may depend on the specific androgen. Medline and Web of Science were searched for all cases of liver tumors associated with androgens. Information from individual cases was entered into a spreadsheet and descriptive statistical analyses were performed. Thirty-six FA cases and 97 non-FA cases with both nonhematologic disorders and acquired aplastic anemia (non-FA AA) were identified. The most common androgens were oxymetholone, methyltestosterone, and danazol. Hepatocellular carcinomas (HCC) were more often associated with oxymetholone and methyltestosterone, while adenomas were associated with danazol. Tumors were reported in six patients who received only parenteral and not oral androgens. FA patients were younger than non-FA patients when androgen use was initiated, and the FA patients developed tumors at younger ages. Non-AA patients were treated with androgens for longer periods of time, compared with FA and non-FA AA patients. All patients on anabolic androgenic steroids are at risk of liver tumors, regardless of underlying diagnosis. The magnitude of the risk cannot be determined from currently available data, because the number of patients receiving androgens is unknown.

My notes (saved in your browser only)

MeSH descriptors

Adenoma, Liver Cell Androgens Carcinoma, Hepatocellular Fanconi Anemia Liver Neoplasms Adenoma, Liver Cell Adenoma, Liver Cell Adult Aged Anabolic Agents Anabolic Agents Androgens Anemia, Aplastic Anemia, Aplastic Anemia, Aplastic Carcinoma, Hepatocellular Carcinoma, Hepatocellular Danazol Danazol Estrogen Antagonists

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (89)

Cited by (6)

Source provenance

openalex
last seen: 2026-05-11T06:09:19.794676+00:00
pubmed
last seen: 2026-10-08T21:02:47.667321+00:00
License: CC0 · commercial use OK